EGb761®

DRUG2 trials

Sponsors

Ipsen

Conditions

Alzheimer's DiseaseCognitive DisordersCognitive Impairment

Phase 2

Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions

CompletedNCT00814346

IpsenAlzheimer's Disease, Cognitive Impairment

Start: 2008-10-31End: 2012-07-31Updated: 2019-02-08

Unknown Phase

EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders

CompletedNCT02321475

IpsenCognitive Disorders

Start: 2014-06-30End: 2015-04-30Updated: 2020-03-31